Approval · Notice of Compliance 25829 · 2021
MINT-HYDROXYCHLOROQUINE: Notice of Compliance 25829
Issued May 10, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25829
- Date
- May 10, 2021
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Updates to product monograph
- Canadian reference product
- PLAQUEENAL (Sanofi-Aventis Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-HYDROXYCHLOROQUINE | Not yet assigned | — |
Medicinal ingredients
- HYDROXYCHLOROQUINE SULFATE 200 MG per TAB